第三章 第三章 雌激素对血液静止的影响
Frank Z Stanczyk1, Intira Sriprasert1, Shinnisha Chulapongwanich2
1Dept of Obstetrics & Gynecology, University of Southern California, Keck School of Medicine, Los Angeles, CA, United States.
Frontiers in endocrinology
|October 6, 2025
概括
雌激素可以通过改变凝血因子来增加血栓形成风险. 新的研究表明,乙醇 (E4) 可能具有中性静血效应,可能为荷尔蒙避孕和治疗提供更安全的替代方案.
科学领域:
- 内分泌学 在内分泌学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 已知雌激素通过影响凝血和抗凝血因子增加动脉和静脉血栓的风险.
- 导致雌激素诱导的血栓形成的精确分子机制尚不清楚,但雌激素类型,剂量和施用途径的变化可能会影响血栓形成的风险.
研究的目的:
- 在激素避孕和激素治疗的背景下,审查不同雌激素的静血作用,包括乙乙醇 (EE),乙醇 (E2) 和乙醇 (E4).
- 评估这些雌激素对静脉血栓塞栓症 (VTE) 风险的影响.
主要方法:
- 关于雌激素对血液静止标志物的影响和绝经前和绝经后妇女的静脉动脉突发症风险现有文献的综述.
- 与不同基于雌激素的避孕药和激素疗法相关的静血样本的比较.
主要成果:
- 联合口服避孕药 (COCs) 中的乙烯基 Estradiol (EE) 和 Estradiol (E2) 显示出微小到较弱的静血效应,EE的静脉瘤风险取决于剂量.
- 新型雌激素乙醇 (E4) 似乎具有中性静血效应.
- 用结合马类雌激素 (CEE) 的激素治疗 (HT) 增加了静脉瘤风险;口服E2的结果是混合的,透皮HT可能具有较小的影响.
结论:
- 雌激素的类型,剂量和途径显著影响静脉静脉动脉平衡和VTE风险.
- 乙醇 (E4) 由于其中性静血特性,可以作为一种更安全的替代品.
- 需要进一步的研究,以充分阐明与各种雌激素配方相关的VTE风险,特别是透皮HT.
关键词:
凝血是凝固的过程.组合口服避孕药是一种口服避孕药.雌激素是一种雌激素.纤维化解是一种纤维化解.血静标志物 血静标志物激素疗法激素疗法是一种激素疗法.绝经后的妇女 绝经后的妇女血栓形成的原因是血栓形成.更多相关视频
06:51Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
Published on: June 7, 2012
59.2K
05:32Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model
Published on: August 11, 2023
2.4K
相关概念视频
01:20Extrinsic and Intrinsic Pathways of Hemostasis
12.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
12.1K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
01:05Introduction to Hemostasis
13.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
13.3K
01:24Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
01:22Hormonal Regulation of the Menstrual Cycle
1.5K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.5K
01:22Formation of the Platelet Plug
8.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.7K